Press releases

  • Patient safety is top priority in medicine and biomedical engineering. Aiming to increase patient safety, the EU introduced the European Medical Device Regulation (MDR) in 2017. Representatives of the medtech sector are expecting massive negative consequences from the regulation and are suggesting specific measures for a revision of the MDR.

    more info
  • Innovative approaches to metastasis research / 2018

    Fraunhofer researcher Prof. Christoph Klein received the “Fidler Innovation Award”


    Researcher Prof. Christoph Klein, Fraunhofer ITEM Division Director of Personalized Tumor Therapy and Senior Professor of Experimental Medicine and Therapy Research at the University of Regensburg (Germany) has been given the international “I.J. ‘Josh‘ Fidler Innovation in Metastasis Research Award”. Prof. Klein received this award for his innovative contributions to metastasis research. The award ceremony took place in Princeton, USA, on August 3, 2018, during the 17th Congress of the Metastasis Research Society.

    more info
  • In the development of new medications and medical engineering, there is a gap between the discovery of new potential active ingredients and products and their further development into medicinal products and medical devices by the industry. The Helmholtz Association and the Fraunhofer-Gesellschaft, together with the Deutsche Hochschulmedizin, have now jointly brought the Proof-of-Concept initiative into being. It promotes the translation of innovative, promising research projects.

    more info
  • Battling infection and resistance / 2018

    Fraunhofer launches German-Australian iCAIR project


    A pioneering collaboration of three partners – Fraunhofer ITEM, the Hannover Medical School (MHH), and Griffith University’s Institute for Glycomics (IfG) in Gold Coast, Australia – was officially launched on January 18, 2018. The aim of the collaborative project iCAIR is to develop new anti-infective drugs.

    more info
  • Bacteriophages join the fight against infection / 2017

    Research alliance launched, aimed at establishing bacteriophages as an approved drug


    (Hannover, Germany) Bacteria worldwide keep developing new resistances to antibiotics. Alternative therapies are urgently needed to meet this challenge. To this end, the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Charité – Universitätsmedizin Berlin, and Charité Research Organisation have teamed up and initiated the project “Phage4Cure”. The goal is to establish bacteriophages as an approved drug for treating bacterial infections. The German Federal Ministry of Education and Research is funding this project with almost four million euros over a period of three years.

    more info
  • The Hannover Science Initiative is celebrating its anniversary: for 10 years now, the 15 partners in the Initiative, among them Hannover’s nine universities and higher-education institutes, the Student Administration, science-affiliated institutions such as the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, hannoverimpuls GmbH, and the State Capital of Hannover, have been successfully cooperating.

    more info
  • Researchers from the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM have teamed up with colleagues from the Hannover Medical School (MHH) and Griffith University’s Institute for Glycomics (IfG) in Gold Coast, Australia, in the iCAIR (Fraunhofer International Consortium for Anti-Infective Research) project. They have set themselves the ambitious goal of closing the gap from the discovery of new agents to their development by the pharmaceutical industry into potential medications and developing new anti-infective drugs.

    more info
  • (Hannover/Germany) The 40 million euro European project eTRANSAFE, kicked off at the end of September 2017, is aimed at speeding up the development of better and safer medicines for patients. Coordinated by the Fundació Institut Mar d'Investigacions Mèdiques (IMIM) and led by the pharmaceutical company Novartis, the project consortium is a public-private partnership of eight academic institutions, six SMEs, and twelve pharmaceutical companies. One of the project partners is Fraunhofer ITEM.

    more info